Medipost Completes Phase 1 and 2a Clinical Trials for Alzheimer's Disease Treatment
[Asia Economy Reporter Cho Hyun-ui] Medipost announced on the 6th that the domestic Phase 1 and 2a clinical trials of the Alzheimer's disease treatment 'Neurostem' have been completed after 5 years.
Neurostem is an Alzheimer's dementia treatment using umbilical cord blood-derived mesenchymal stem cells, aiming to inhibit neuronal cell death through mechanisms such as reducing amyloid beta and blocking hyperphosphorylation of tau protein.
Since 2014, Medipost has evaluated safety and exploratory efficacy in a total of 46 patients, including 10 in Phase 1 and 36 in Phase 2, at Samsung Seoul Hospital.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Contracts Signed Without Viewing at 1.6 Billion Won"... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- [Breaking] Blue House expresses "deep regret over Samsung negotiation breakdown... urges both sides to do their best for a final agreement"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A Medipost official stated, "Unlike most treatments currently under development, Neurostem features a complex therapy through various mechanisms," adding, "It will show new possibilities for Alzheimer's disease treatment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
